Sona Nanotech
eröffnet am 27.03.20 13:48:51 von
neuester Beitrag 11.03.24 22:58:51 von
neuester Beitrag 11.03.24 22:58:51 von
Beiträge: 56
ID: 1.322.527
ID: 1.322.527
Aufrufe heute: 0
Gesamt: 6.485
Gesamt: 6.485
Aktive User: 0
ISIN: CA83541C1059 · WKN: A2N64Z · Symbol: SONA
0,3400
CAD
-2,86 %
-0,0100 CAD
Letzter Kurs 01.05.24 CSE
Neuigkeiten
Werte aus der Branche Nanotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,1700 | +9,35 | |
| 0,9900 | +2,59 | |
| 4,6300 | +1,31 | |
| 0,7390 | +0,07 | |
| 76,50 | 0,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5200 | -1,89 | |
| 174,00 | -2,25 | |
| 2,0800 | -3,03 | |
| 32,00 | -3,32 | |
| 1,3000 | -3,70 |
Beitrag zu dieser Diskussion schreiben
Feedback
Sona Nanotech in den letzten 2 Tagen mit steilem Ausbruch aus der
über einjährigen Konsolidierungsformation
"What differentiates Sona Nanotech from other companies trying to develop cancer therapy using nanotechnology, aside from SivaLum, is their unique GNRs. In addition to 1/ their exclusive, detergent-free manufacturing process 2/ gold nanorods have close to twice the tested thermal efficiency of gold nanoshells with silica core used by some (55% vs 30%). So, Sona's IP protection is essential for its success as the company knows. Sona/Siva/Dr. Giamontonio are on to something. With proper advice and guidance from Shepard Bently and the EXCITE group of senior surgeons and health care payors Sona has just as much chance as anyone to become one of the first non-toxic, non-surgical, well tolerated, commercially accepted cancer treatments." @landgreen
über einjährigen Konsolidierungsformation
"What differentiates Sona Nanotech from other companies trying to develop cancer therapy using nanotechnology, aside from SivaLum, is their unique GNRs. In addition to 1/ their exclusive, detergent-free manufacturing process 2/ gold nanorods have close to twice the tested thermal efficiency of gold nanoshells with silica core used by some (55% vs 30%). So, Sona's IP protection is essential for its success as the company knows. Sona/Siva/Dr. Giamontonio are on to something. With proper advice and guidance from Shepard Bently and the EXCITE group of senior surgeons and health care payors Sona has just as much chance as anyone to become one of the first non-toxic, non-surgical, well tolerated, commercially accepted cancer treatments." @landgreen
Sona Nanotech Closes Acquisition of Siva Therapeutics,
Plans For First Therapy Application for Colorectal Cancer
https://www.newsfilecorp.com/release/159567
Plans For First Therapy Application for Colorectal Cancer
https://www.newsfilecorp.com/release/159567
Sona Nanotech Receives Technology Assessment Results from NCL
"The results of the NCL's characterization of Sona's biocompatible gold nanorod nanoparticles indicate that they are expected to be compatible for use in vivo with Siva's Targeted Hyperthermia Therapy, as ruling out the material presence of endotoxins was key to enabling our further work together towards preparations for clinical trials," Sona's CEO, David Regan and Siva Therapeutic's CEO, Len Pagliaro, Ph.D. jointly commented.
https://ca.finance.yahoo.com/news/sona-nanotech-receives-tec…
"The results of the NCL's characterization of Sona's biocompatible gold nanorod nanoparticles indicate that they are expected to be compatible for use in vivo with Siva's Targeted Hyperthermia Therapy, as ruling out the material presence of endotoxins was key to enabling our further work together towards preparations for clinical trials," Sona's CEO, David Regan and Siva Therapeutic's CEO, Len Pagliaro, Ph.D. jointly commented.
https://ca.finance.yahoo.com/news/sona-nanotech-receives-tec…
Sona Nanotech to Acquire Cancer Therapy Developer Siva Therapeutics
January 26, 2023
https://www.newsfilecorp.com/release/152661
January 26, 2023
https://www.newsfilecorp.com/release/152661
Sona Announces U.S. Partnership and Preliminary Evaluation Results for Its COVID-19 Saliva Test
Halifax, Nova Scotia--(Newsfile Corp. - November 8, 2021) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it has entered into a binding licensing agreement with U.S. Food and Drug Administration ("FDA") registered Arlington Scientific Inc. ("ASI" or "Arlington") of Springville, Utah, an in-vitro diagnostics developer, manufacturer and distributor, to bring Sona's rapid saliva COVID-19 test to market. Under the terms of the agreement, Sona licenses the intellectual property for its rapid saliva COVID-19 test and ASI undertakes to secure an FDA Emergency Use Authorization ("EUA") for point-of-care and at-home use for the test and any necessary associated activities, including medical ethics review board approval, the coordination and underwriting of US-based clinical and any other studies, and FDA EUA application submissions and follow-up. If an FDA EUA is granted, Arlington will coordinate manufacturing and distribution of the test in the U.S. exclusively on a profit-sharing basis by which it would also earn a share of any of Sona's profits from international sales.
https://www.newsfilecorp.com/release/102507
Halifax, Nova Scotia--(Newsfile Corp. - November 8, 2021) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it has entered into a binding licensing agreement with U.S. Food and Drug Administration ("FDA") registered Arlington Scientific Inc. ("ASI" or "Arlington") of Springville, Utah, an in-vitro diagnostics developer, manufacturer and distributor, to bring Sona's rapid saliva COVID-19 test to market. Under the terms of the agreement, Sona licenses the intellectual property for its rapid saliva COVID-19 test and ASI undertakes to secure an FDA Emergency Use Authorization ("EUA") for point-of-care and at-home use for the test and any necessary associated activities, including medical ethics review board approval, the coordination and underwriting of US-based clinical and any other studies, and FDA EUA application submissions and follow-up. If an FDA EUA is granted, Arlington will coordinate manufacturing and distribution of the test in the U.S. exclusively on a profit-sharing basis by which it would also earn a share of any of Sona's profits from international sales.
https://www.newsfilecorp.com/release/102507
Trading Spotlight
Sona Secures Clinical Trial Authorization and Hospital Partner
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Halifax, Nova Scotia—(Newsfile Corp. – April 12, 2021) –Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona“) a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has been granted Health Canada Investigational Testing Authorization for a clinical trial of the Sona Saliva C-19 Rapid Test, a saliva sample-based rapid COVID-19 antigen test, with the Humber River Hospital in Toronto. The trial is expected to commence shortly, following final ethics review board sign-off of the trial protocol amendments required by Health Canada. The trial’s objective is to determine the clinical performance of the test when compared to RT-PCR, in symptomatic patients. Analytical validation studies would also be required to support any regulatory submissions.
https://youtu.be/q36bllrvEDQ
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Halifax, Nova Scotia—(Newsfile Corp. – April 12, 2021) –Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona“) a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has been granted Health Canada Investigational Testing Authorization for a clinical trial of the Sona Saliva C-19 Rapid Test, a saliva sample-based rapid COVID-19 antigen test, with the Humber River Hospital in Toronto. The trial is expected to commence shortly, following final ethics review board sign-off of the trial protocol amendments required by Health Canada. The trial’s objective is to determine the clinical performance of the test when compared to RT-PCR, in symptomatic patients. Analytical validation studies would also be required to support any regulatory submissions.
https://youtu.be/q36bllrvEDQ
Habs auch nicht gesehen.
Ja der Profiftrader ist schon wieder ausgeschieden nach dem Post.. was hatter erd en gesagt ?
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Tatsachenbehauptung ohne Beleg, bitte Quelle nachvollziehbar benennen oder als eigene Meinung kennzeichnen!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: bitte das Threadthema beachten, Werbung für threadfremde Aktien bitte unterlassen
Durchsuchen
